Category: Other Business News

Bioptigen Press Release - Devices become first OCT systems cleared for hand-held ophthalmic imaging of children Bioptigen Inc. has received 510(k) clearance from the U.S. Food and Drug Administration to begin marketing its hand-held Envisu Spectral Domain Ophthalmic Imaging System (SDOIS) devices for patient use. The Envisu SDOIS aids in the diagnosis of physiological and pathological conditions of the eye through non-contact optical imaging. In receiving this regulatory clearance, Bioptigen’s Envisu SDOIS become the first optical coherence tomography imaging systems commercially available in the United States for hand-held and pediatric imaging. Envisu’s ergonomic, hand-held scanner enables imaging ...

Facing a 60% reduction in the fee for optical coherence tomography (OCT) tests, as well as a 44% reduction in fees associated with medicinal eye injections, Hillson is concerned he won’t be able to continue caring for patients who were already struggling to afford the care...Recognizing his patients — the majority of whom are elderly — prefer not to travel, Hillson is also struggling with whether it will be cost effective to maintain his OCT testing machine, which is the only one in Orillia. Because many of the conditions he diagnoses and treats need immediate attention to save sight, having ...

Several hundred fees paid to Ontario doctors are going under the knife as the province's minority Liberals forge ahead with a wage freeze for physicians after labour negotiations fell apart last week...Some of the changes will affect patients, such as delisting joint/spine manipulation services and limiting optical coherence tomography for patients with retinal disease or glaucoma to four times a year.

Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the 11th Annual JMP Securities Research Conference on Monday, May 14.The presentation by John Dahldorf, chief financial officer, will begin at 10:30 a.m., Pacific Daylight Time (1:30 p.m., Eastern Daylight Time). The presentation will be available through the conference website at http://www.wsw.com/webcast/jmp17/volc/ and via the company's website at www.volcanocorp.com. Volcano Corporationis ...

Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8.The presentation by John Dahldorf, chief financial officer, will begin at 4:10 p.m., Eastern Daylight Time (1:10 p.m., Pacific Daylight Time).

Optovue Press Release: Optovue Announces FDA 510(k) Clearance of the RTVue XR TM FD-OCT RTVue XR is being premiered at the Annual Meeting of the American Society of Cataract and Refractive Surgeons FREMONT, CA, April 23, 2012 – Optovue, a pioneer in spectral-domain optical coherence tomography (SD-OCT), announces that it has received FDA 510(k) clearance of the XR version of their flagship RTVue ® FD-OCT system. Bringing 70,000 A-scans-per-second to spectral-domain OCT, the updated XR version offers clinicians speed that no currently cleared SD-OCT system can match. Together with real-time tracking and the updated SharpVue TM feature, the speed ...

Abbott (NYSE: ABT) and St. Jude Medical (NYSE: STJ) today announced Choice Alliance, a multi-year joint initiative that provides mutual U.S. customers access to a robust portfolio of interventional cardiology, cardiac rhythm management, electrophysiology and intravascular imaging and diagnostic technologies.This enhanced alliance, which builds upon an existing agreement between the two companies that began in 2008, includes Abbott's leading coronary and endovascular product portfolios, including the XIENCE family of everolimus eluting coronary stents, and St. Jude Medical's portfolio of electrophysiology, cardiac rhythm management and cardiology technologies, including ablation catheters, pacemakers, implantable cardioverter defibrillators (ICDs), leads, fractional ...

Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will report its operating results for the first quarter of fiscal 2012 on Wednesday, May 2.The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time), Wednesday, May 2, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. The teleconference can ...

Our optical coherence tomography or OCT product revenue increased more than 75% on a year-over-year basis during the first quarter. This extraordinary growth was driven partly by the success of our new ILUMIEN hardware platform, which combines both OCT and fractional flow reserve or FFR capabilities into a single system. We estimate that we already hold approximately a 15% share of the $500 million market for intravascular imaging with our OCT technology, even though our clinical trial programs and other market development efforts supporting the expanded use of OCT products are still in their infancy. Here again, we expect our ...

Exalos Press Release - EXALOS AG has introduced its new EBR370000 series of balanced receivers. The balanced receiver family covers wavelength ranges from 400nm to 1600nm. The EXALOS Balanced Receiver (EBR) is engineered to support challenging applications such as Optical Coherence Tomography (OCT) where high signal-to-noise performance is critical. The EBR370000 devices achieve the lowest noise performance of balanced receivers in this bandwidth region. These receivers feature a compact design and a single 5V supply voltage for OEM applications and allow for electrically switching the gain or for continuously adjusting the bandwidth. Key Features: Continuously adjustable bandwidth from 60 MHz to ...

The Photonics Laboratories of Nippon Telegraph and Telephone Corporation (NTT) in Japan have developed a new swept light source operating at an A-line rate of 200 kHz. The swept light source was demonstrated at the 2012 BiOS exhibition, and received a favorable reception from OCT-relatedengineers. The swept light source is based on a Littman-Metcalf external cavity laser diode that incorporates an electro-optic (EO) KTN (KTa1-xNbxO3) deflector. The KTN deflector provides a fast and fairly large light deflection as a result of a non-uniform electric field generated by injected carriers. The deflector is a promising candidate for application to light sources ...

Olympus Corp. , the Japanese camera maker that admitted to a 13-year cover-up of investment losses, said it received capital alliance offers from Sony Corp. ,Fujifilm Holdings Corp.  and Terumo Corp.  Olympus got offers from “more than three” potential partners and may decide as early as next month whether to form a tie-up, President-designate Hiroyuki Sasa said in an interview in Tokyo today. He didn’t name the others. The company plans to release its business plan as early as May, he said at Olympus headquarters.

Heidelberg Engineering Press Release: Heidelberg Engineering GmbH, the leading developer of laser diagnostics for ophthalmic applications, announced today that the United States Food and Drug Administration (FDA) has granted clearance for the new, SPECTRALIS® Anterior Segment Module (ASM). The Anterior Segment Module provides high-resolution images of cornea, anterior chamber angle and sclera utilizing unique Heidelberg Noise Reduction™ technology for enhanced detail. Clinicians can assess both chamber angles at the same time using a 16mm-wide angle-to-angle OCT scan. “The SPECTRALIS Anterior Segment Module paves the way towards digital gonioscopy”, said Sanjay Asrani, MD, Associate Professor of Ophthalmology, Duke University Eye Center ...

Imalux Corporation ("Imalux"), a medical device company and developer of the Niris® Imaging System based on Optical Coherence Tomography (OCT) technology, today announced receipt of the CE Mark. Worldwide commercial shipments of the real-time, site of care Niris 1300e tissue microstructure Imaging System have begun. The University of North Carolina, Charlotte has received the first system in the USA. Additional systems will be delivered to the University of Magdeburg and University of Munich-Grosshadern in Germany over the next several weeks. Niris provides an "optical biopsy" for real-time visualization of tissue changes that occur in the earliest stages of disease, while ...

Imalux out of Cleveland, Ohio received the CE Mark for the Niris 1300e tissue imaging system. The device is used to scan epithelial tissue for signs of disease, essentially like an optical biopsy. It relies on near-infrared optical coherence tomography which doesn’t damage the tissue it’s analyzing, while providing real-time cross-sectional visualization via the attached computer. The probe is sterilizable and can also be used inside a single-use semi-rigid sheath to minimize cleaning between patients.